Convalo Health International (CXV:TSXV) was the third most liquid stock on the TSX Venture Wednesday.

The healthcare-related stock has taken the Venture by storm in recent weeks and is being led by former CEO of Patient Home Monitoring, Michael Dalsin. Dalsin remains the Chairman of PHM and is the Chairman and CEO of Convalo.

Convalo Health jumps 7% on 7 million traded


Convalo Health, one of the latest and most dynamic healthcare-related stocks on the TSX Venture, servicing the addictions and mental illness markets primarily in the US, to break out, had another epic day in the markets Wednesday.

The stock rallied 7%, after hitting a new all-time high of $0.46 per share, to close at $0.445 after more than 7 million shares traded hands.


Convalo Health reacts to changing US Health Care System


Convalo Health‘s business model is in many ways is built on the relatively recent reformation of US laws impacting the US Health Care System.

The phrase ‘Mental Health Parity’ which Convalo cites on its website has become more prevalent in the 21st century as mental illness and the treatment options for mental illnesses increase.

In short, mental parity and its implications on health services in the U.S., that US Congress is now forcing health insurance coverage for addiction treatment, has changed dramatically.

Below is an excerpt from Convalo Health’s website:

“The Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA) requires group health plans and health insurance issuers to ensure that financial requirements (such as co-pays, deductibles) and treatment limitations (such as visit limits) applicable to mental health or substance use disorder (MH/SUD) benefits are no more restrictive than the predominant requirements or limitations applied to substantially all medical/surgical benefits.”



Convalo explains on its website that Obamacare was signed into law on March 23, 2010 by President Barack Obama.

“Under Obamacare, many Americans making under 400% of the federal poverty level (FPL) will qualify for cost assistance subsidies through the marketplace. Cost assistance comes in three forms: Premium tax credits for reduced premium costs, cost sharing subsidies for reduced out-of-pocket costs, and Medicaid and CHIP.”



The company is hopeful this access to more affordable healthcare, including mental healthcare will make their expansion plans occur more fluidly.

Michael Dalsin: a tale of two companies

Dalsin is the Chairman and CEO of Convalo and the current Chairman and former CEO of Patient Home Monitoring (TSXV:PHM).

PHM has been one of the best performing stocks on the TSX Venture in the past 12 months and has seen its market cap rise to over $300 million lately. Clearly, Dalsin is hoping he can achieve similar success at Convalo.

While not related to Convalo, Mr. David Hayes the CEO of healthcare services company Patient Home Monitoring (PHM:TSXV) and his past successes are revealed in our latest EBook which is focused on 50 of North America’s top leaders who took start-ups to stunning multimillion dollar buyouts.

The creation of wealth outlined in this new exclusive report is stunning. Click the below image and link to download your free copy.


Convalo Health’s business model is to search out potential acquisition targets. This has worked well for a handful of TSX Venture healthcare-related stocks, including Patient Home Monitoring.

Convalo explains on its website that it plans to acquire up to 20 in the next 4 years of the more than 1000 small, clinically focused treatment centers in the US.

Retail investors are now waiting for Convalo to announce its next acquisition.

In Convalo Health‘s investor presentation it states that insiders own 27 million shares of the company. There are currently approximately 106 million outstanding.



This article represents solely the opinions of Alexander Smith. Alexander Smith is not an investment advisor and any reference to specific securities in the list referred to in the article does not constitute a recommendation thereof. Readers are encouraged to consult their investment advisors prior to making any investment decisions. The information in this article is of an impersonal nature and should not be construed as individualized advice or investment recommendations.

This is not an invitation to purchase any securities mentioned in this report. Pinnacle Digest does not endorse or recommend any of the referenced securities. At the time of publication and distribution of this report (2:00PM PST on March 25, 2015) neither, its employees or consultants owned shares in any of the mentioned companies in this report. This article is intended for informational and entertainment purposes only. The author of this article bears no liability for losses and/or damages arising from the use of this article. This report may contain technical or other inaccuracies, omissions, or typographical errors, for which and its parent company assumes no responsibility. We do not guarantee that any of the companies mentioned in this report or on will perform as we expect, and any comparisons we have made to other companies may not be valid or come into effect.

All statements in this report, other than statements of historical fact, should be considered forward-looking statements. These statements relate to future events or future performance. Much of this report is comprised of statements of projection. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. and its employees are not a registered broker-dealer or financial advisors. Before investing in any securities, you should consult with your financial advisor and a registered broker-dealer. Nothing in this article should be construed as a solicitation to buy or sell any securities. This article is intended for informational and entertainment purposes only. The author of this article bears no liability for losses and/or damages arising from the use of this article.